Senores Pharmaceuticals Share Price

NSE
SENORES •
BUY

1W Return

1M Return

6M Return

1Y Return

3Y Return

The current prices are delayed, login or Open Demat Account for live prices.
Start SIP in Senores Pharmaceuticals
Senores Pharmaceuticals Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Senores Pharmaceuticals Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
-1.4
Dividend yield 1yr %
0

Senores Pharmaceuticals Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Senores Pharmaceuticals Quarterly Revenue

Dec 2024Mar 2024Dec 2023
103.02 Cr
214.52 Cr
78.7 Cr

Senores Pharmaceuticals Yearly Revenue

Mar 2024Mar 2023Mar 2022
217.34 Cr
39.02 Cr
14.63 Cr

Senores Pharmaceuticals Quarterly Net Profit/Loss

Dec 2024Mar 2024Dec 2023
16.43 Cr
32.7 Cr
7.12 Cr

Senores Pharmaceuticals Yearly Net Profit/Loss

Mar 2024Mar 2023Mar 2022
32.71 Cr
8.43 Cr
0.99 Cr
Senores Pharmaceuticals Result Highlights
  • Senores Pharmaceuticals Ltd reported a - quarter-on-quarter (QoQ) - in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 36.1%.

  • Its expenses for the quarter were - by - QoQ and up 26.6% YoY.

  • The net profit - - QoQ and increased 130.8% YoY.

  • The earnings per share (EPS) of Senores Pharmaceuticals Ltd stood at 5 during Q3FY25.

    Read more

Data Source: BSE, Company announcements

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

Senores Pharmaceuticals shareholding Pattern

Promoter
45.8%
Foreign Institutions
4.2%
Mutual Funds
3.2%
Domestic Institutions
9.6%
Public
40.4%
Promoter
45.8%
Foreign Institutions
4.2%
Mutual Funds
5%
Domestic Institutions
11.8%
Public
38.2%

Senores Pharmaceuticals Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
0
Bearish Moving Averages
11
5Day EMA
519.60
10Day EMA
528.50
12Day EMA
531.40
20Day EMA
540.40
26Day EMA
544.50
50Day EMA
547.90
EMA
EMA
5Day SMA
521.00
10Day SMA
534.20
20Day SMA
541.90
30Day SMA
561.40
50Day SMA
555.30
SMA
SMA
SMA
Delivery & Volume

Delivery & Volume

PeriodCombined Delivery VolumeNSE+BSE Traded Volume
Day Rs
66911 Rs
173237 Rs
Week Rs
103054 Rs
278647 Rs
Month Rs
170763 Rs
504909 Rs
Resistance & Support
512.15
Pivot
Resistance
First Resistance
518.65
Second Resistance
527.35
Third Resistance
533.85
Support
First Support
503.45
Second support
496.95
Third Support
488.25
Relative Strength Index
38.29
Money Flow Index
32.64
MACD
-13.06
MACD Signal
-9.32
Average True Range
28.32
Average Directional Index
20.40
Rate of Change (21)
-13.82
Rate of Change (125)
0.00

Senores Pharmaceuticals Latest News

23 APR 2025 | Wednesday

Senores Pharmaceuticals Ltd - 544319 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

22 APR 2025 | Tuesday

Senores Pharmaceuticals Ltd - 544319 - Update In Respect Of Our Intimations Dated March 11, 2025 And March 12, 2025, Pursuant To Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('Listing Regulations')

19 APR 2025 | Saturday

Senores Pharmaceuticals Ltd - 544319 - Intimation For Change In Contact Details Of MUFG Intime India Private Limited, Registrar And Share Transfer Agent (RTA) Of The Company.

View More

Senores Pharmaceuticals Company background

Founded in: 2017
Managing director: SWAPNIL JATINBHAI SHAH
Senores Pharmaceuticals Limited was originally incorporated as Senores Pharmaceuticals Private Limited through a Certificate of Incorporation dated December 26, 2017, issued by the Registrar of Companies, Central Registration Centre. Thereafter, the name of the Company was changed to Senores Pharmaceuticals Limited upon conversion to a Public Limited Company and a fresh Certificate of Incorporation dated September 4, 2023, was issued by the RoC to the Company. Senores Pharma is a global research driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for Regulated Markets across various therapeutic areas and dosage forms. The Regulated Markets business is focused on Regulated Markets of US and Canada. The Company has adopted a strategy of identifying, developing and commercializing specialty and complex niche products in the midmarket range and received approvals for 19 ANDAs. Further, it develop and manufacture pharmaceutical products across various therapeutic areas for Emerging Markets, having a presence across 43 countries. The Company operate a Critical Care Injectables Business, supplying critical care injectables to hospitals across India through distributors, and manufacture APIs for the domestic market and SAARC countries.In 2021, the Company incorporated a wholly owned subsidiary, Senores Pharmaceuticals Inc in the US. It then entered the new segment of API by acquiring Ratnagene Lifescience Private Limited. The Company started domestic business with the launch of the Critical Care Injectables Business in 2022.The Company further acquired majority stake in Havix Group Inc., making it a subsidiary of the Company in 2023. It consolidated presence in emerging markets by acquiring shares in Ratnatris Pharmaceuticals Private Limited, making it a Subsidiary of the Company in 2023. The Company has launched CMO product in the US with Jubilant Cadista Pharmaceuticals Inc., in 2024. The Company is planning to raise money from public through IPO by issue and allotment of 2,700,000 Equity Shares through Offer for Sale and Rs 500 Crores equity funds through Fresh Issue.
Read More

Senores Pharmaceuticals FAQs

Senores Pharmaceuticals share price is ₹504.95 in NSE and ₹506.45 in BSE as on 30/4/2025.

Senores Pharmaceuticals share price in the past 1-year return was 0. The Senores Pharmaceuticals share hit a 1-year low of Rs. 435.25 and a 1-year high of Rs. 665.

The market cap of Senores Pharmaceuticals is Rs. 2348.5 Cr. as of 30/4/2025.

The PE ratios of Senores Pharmaceuticals is 0 as of 30/4/2025.

The PB ratios of Senores Pharmaceuticals is 3.19 as of 30/4/2025

The Mutual Fund Shareholding in Senores Pharmaceuticals was 3.23% at the end of 30/4/2025.

You can easily buy Senores Pharmaceuticals shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Please be aware that Senores Pharmaceuticals stock prices are subject to continuous fluctuations due to various factors.

Open Demat Account
+91 -

personImage
Open Demat Account
+91 -